September 19th 2024
"But for physicians considering chemotherapy for which there is equipoise, the Decipher test could be used to swing the decision one way or the other," says Gerhardt Attard, MD, PhD, FRCP.
September 16th 2024
Hollings' SC AMEN Program for prostate cancer screening launches with enthusiastic support
January 24th 2022“I think this is a tremendous opportunity for the Black community and for Black men. I hope my story can encourage other men to get prostate cancer screenings and possibly save a life. Every life is important," says Larry J. Ferguson, DMD.
Unexpected increase in PSA testing after USPSTF recommendations
January 21st 2022"It is worth remembering that injudicious use of PSA test, and the downstream consequences of overtreatment and complications, can obscure the benefits associated with PSA-based early detection of prostate cancer," writes Badar M. Mian, MD.
Combination ADT and radiation therapy shows favorable outcomes in men with localized prostate cancer
January 18th 2022“Our team showed that treating a group of approximately 10 to 15 men with hormone therapy or extended adjuvant hormone therapy, for at least 18 months, prevented one man from developing metastatic disease 10 years after treatment," says Daniel E. Spratt, MD.
Analysis shows strength of abiraterone/ADT efficacy in non-metastatic prostate cancer
January 18th 2022The combination of abiraterone acetate, prednisolone, and androgen deprivation therapy (ADT) with or without enzalutamide delivers a strong metastasis-free survival boost versus treatment with ADT alone in patients with high-risk non-metastatic prostate cancer.
Survival with frontline abiraterone higher for African American vs White men with mCRPC
January 11th 2022This real-world cohort study corroborates prior research showing a greater clinical benefit for abiraterone acetate in African American versus White patients with metastatic castration-resistant prostate cancer.
Dr. Linehan on advancements in minimally invasive and robotic technologies
January 7th 2022“I think in specialized cases, especially for patients [who] need focal therapy or want focal therapy, or [for whom] you're really trying to minimize any nerve damage or urethral damage…these are excellent therapies,” says Jennifer Linehan, MD.
Marking 5 decades of progress in cancer care
January 4th 2022"As we celebrate the tremendous victories against cancer and commemorate 5 decades of progress, we are also reminded of the harsh reality that we have a war still to be won," writes Michael S. Cookson, MD, MMHC, co–editor in chief of Urology Times.
Assessing the efficacy of enzalutamide plus ADT in oligometastatic prostate cancer
December 23rd 2021At the 2021 SUO Annual Meeting, Andrew J. Armstrong, MD, MSc, presented promising findings from the study, “The efficacy of enzalutamide (Enza) plus androgen deprivation therapy (ADT) on oligometastatic hormone-sensitive prostate cancer: extended post hoc analysis of ARCHES.”
Dr. Andriole discusses targeted therapies in men with prostate cancer who demonstrate BCR
December 14th 2021“Men who experience biochemical recurrence after radical prostatectomy or radiation therapy should undergo PET scanning so that they can have specific targeted treatments administered to the site or sites of recurrence rather than [be treated] using the historical type of clinical parameters that we used in the past,” says Gerald L. Andriole, MD.
Optimization of Genetic Testing for mCRPC
Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.